Prodrug activation enzymes in cancer gene therapy

Among the broad array of genes that have been evaluated for tumor therapy, those encoding prodrug activation enzymes are especially appealing as they directly complement ongoing clinical chemotherapeutic regimes. These enzymes can activate prodrugs that have low inherent toxicity using both bacterial and yeast enzymes, or enhance prodrug activation by mammalian enzymes. The general advantage of the former is the large therapeutic index that can be achieved, and of the latter, the non‐immunogenicity (supporting longer periods of prodrug activation) and the fact that the prodrugs will continue to have some efficacy after transgene expression is extinguished. This review article describes 13 different prodrug activation schemes developed over the last 15 years, two of which – activation of ganciclovir by viral thymidine kinase and activation of 5‐fluorocytosine to 5‐fluorouracil – are currently being evaluated in clinical trials. Essentially all of these prodrug activation enzymes mediate toxicity through disruption of DNA replication, which occurs at differentially high rates in tumor cells compared with most normal cells. In cancer gene therapy, vectors target delivery of therapeutic genes to tumor cells, in contrast to the use of antibodies in antibody‐directed prodrug therapy. Vector targeting is usually effected by direct injection into the tumor mass or surrounding tissues, but the efficiency of gene delivery is usually low. Thus it is important that the activated drug is able to act on non‐transduced tumor cells. This bystander effect may require cell‐to‐cell contact or be mediated by facilitated diffusion or extracellular activation to target neighboring tumor cells. Effects at distant sites are believed to be mediated by the immune system, which can be mobilized to recognize tumor antigens by prodrug‐activated gene therapy. Prodrug activation schemes can be combined with each other and with other treatments, such as radiation, in a synergistic manner. Use of prodrug wafers for intratumoral drug activation and selective permeabilization of the tumor vasculature to prodrugs and vectors should further increase the value of this new therapeutic modality. Copyright © 2000 John Wiley & Sons, Ltd.

[1]  T. A. Connors,et al.  Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity , 1966, Nature.

[2]  L. M. Cobb,et al.  2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. , 1969, Biochemical pharmacology.

[3]  W. Ross,et al.  Tumour-growth inhibitorynitrofphenylaziridines and related compounds structure-activity relationships , 1969 .

[4]  T. A. Connors.  Alkylating agents. , 1990, Cancer chemotherapy and biological response modifiers.

[5]  S. Venitt.  The differential response of resistant and sensitive strains of Escherichia coli to the cytotoxic effects of 5-aziridino-2,4-dinitrobenzamide (CB1954). , 1971, Chemico-biological interactions.

[6]  M. Boyd,et al.  Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. , 1972, Nature: New biology.

[7]  W. Shearer,et al.  Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. , 1973, Journal of immunology.

[8]  C. Wilson,et al.  Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. , 1975, Journal of neurosurgery.

[9]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[10]  L. Helson,et al.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. , 1981, Journal of neurosurgery.

[11]  F. Moolten.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.

[12]  S. Weller,et al.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant , 1988, Journal of virology.

[13]  F. Hochberg,et al.  High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. , 1989, Journal of neurosurgery.

[14]  D. Faulds,et al.  Ganciclovir , 2012, Drugs.

[15]  F. Moolten,et al.  Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. , 1990, Journal of the National Cancer Institute.

[16]  R. Martuza,et al.  Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. , 1991, The New biologist.

[17]  B. Mitchell,et al.  Cloning and expression of human deoxycytidine kinase cDNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Scharfmann,et al.  Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Korzekwa,et al.  Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. , 1991, Cancer research.

[20]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). , 1992, Biochemical pharmacology.

[22]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[23]  R. Martuza,et al.  Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cells , 1992, Journal of neuroscience research.

[24]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[25]  J. Barrett,et al.  Gap junction function and cancer. , 1993, Cancer research.

[26]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[28]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.

[29]  E K Fishman,et al.  Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. , 1993, Cancer research.

[30]  F. Moolten,et al.  Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. , 1993, Human gene therapy.

[31]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[32]  C. Richards,et al.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Z. Bebők,et al.  Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. , 1994, Gene therapy.

[34]  K. Sikora.  Genetic approaches to cancer therapy. , 1994, Gene therapy.

[35]  X. Breakefield,et al.  Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. , 1994, Cancer gene therapy.

[36]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[37]  R. Blaese,et al.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.

[38]  J. Park,et al.  Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. , 1994, Cancer research.

[39]  N. Minton,et al.  Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. , 1994, FEMS microbiology letters.

[40]  T. Shawker,et al.  The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. , 1994, Journal of neurosurgery.

[41]  F. Gage,et al.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Meruelo,et al.  'Bystander killing' induces apoptosis and is inhibited by forskolin. , 1995, Gene therapy.

[43]  F. M. Huennekens,et al.  Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. , 1995, Cancer research.

[44]  D. Ilsley,et al.  Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. , 1995, Biochemistry.

[45]  T. A. Connors.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995, Gene therapy.

[46]  A. Harris,et al.  Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. , 1995, British Journal of Cancer.

[47]  C. Springer,et al.  Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. , 1995, European journal of cancer.

[48]  D. Waxman,et al.  Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. , 1995, Cancer research.

[49]  S. Kim,et al.  Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. , 1995, International journal of radiation oncology, biology, physics.

[50]  Connors Ta.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .

[51]  M. Israel,et al.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  X. Breakefield,et al.  Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  S. Nesnow,et al.  4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1. , 1995, Biochemical pharmacology.

[54]  D. Klatzmann,et al.  Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". , 1996, Cancer gene therapy.

[55]  D. Waxman,et al.  Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.

[56]  B. Mitchell,et al.  Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. , 1996, Cancer research.

[57]  P. Wen,et al.  In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. , 1996, Human gene therapy.

[58]  C. Mullen,et al.  Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. , 1996, Cancer research.

[59]  M. Black,et al.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  G. Harsh,et al.  Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. , 1996, Cancer gene therapy.

[61]  P. Wen,et al.  Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo , 1996, Nature Medicine.

[62]  T. Tamiya,et al.  Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. , 1996, Cancer gene therapy.

[63]  G. van Kaick,et al.  Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[65]  R G Blasberg,et al.  Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. , 1996, Cancer research.

[66]  T. Tamiya,et al.  Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. , 1997, Human gene therapy.

[67]  C. Naus,et al.  Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. , 1997, Cancer research.

[68]  M. Dewhirst,et al.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.

[69]  Z. Ram,et al.  Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment , 1997, Gene Therapy.

[70]  V. Cherington,et al.  The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions , 1997, Gene Therapy.

[71]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[72]  C. Springer,et al.  The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. , 1997, Human gene therapy.

[73]  D. Waxman,et al.  Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. , 1997, Cancer research.

[74]  D. Klatzmann,et al.  A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. , 1997, Human gene therapy.

[75]  J. Montgomery,et al.  In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. , 1997, Human gene therapy.

[76]  C. J. McGrath,et al.  Effect of exchange rate return on volatility spill-over across trading regions , 2012 .

[77]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[78]  M. Izquierdo,et al.  Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer , 1997, Gene Therapy.

[79]  S. Kim,et al.  Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. , 1997, Human gene therapy.

[80]  A. Elshami,et al.  Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy , 1997, Gene Therapy.

[81]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial , 1997, Cancer Chemotherapy and Pharmacology.

[82]  E. Chiocca,et al.  The effect of ganciclovir on herpes simplex virus-mediated oncolysis. , 1997, The Journal of surgical research.

[83]  C. Denning,et al.  Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. , 1997, Human gene therapy.

[84]  C. Morton,et al.  Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. , 1998, Cancer research.

[85]  E. Neuwelt,et al.  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.

[86]  C. Springer,et al.  Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase , 1998, Gene Therapy.

[87]  J. Simons,et al.  Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. , 1998, Seminars in oncology.

[88]  W. Anderson,et al.  Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[90]  C. Beauséjour,et al.  Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. , 1998, Human gene therapy.

[91]  J. Neyts,et al.  Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells , 1998, Gene Therapy.

[92]  W. Ramsey,et al.  Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. , 1998, Human gene therapy.

[93]  X. Breakefield,et al.  Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. , 1998, Journal of the National Cancer Institute.

[94]  D. Waxman,et al.  Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. , 1998, Cancer research.

[95]  J. Gebert,et al.  Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. , 1998, Human gene therapy.

[96]  Y. Shiratori,et al.  Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. , 1998, Cancer research.

[97]  K. Dobberstein,et al.  New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. , 1998, Human gene therapy.

[98]  D Artemov,et al.  Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. , 1998, Cancer research.

[99]  R. Crystal,et al.  In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. , 1998, The Journal of clinical investigation.

[100]  C. Morton,et al.  Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). , 1998, Cancer research.

[101]  W. Ramsey,et al.  The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication , 1998, Gene Therapy.

[102]  Y. Vergouwe,et al.  Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration , 1998, Gene Therapy.

[103]  F. Pedersen,et al.  RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. , 1998, Human gene therapy.

[104]  X. Breakefield,et al.  Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.

[105]  P F Morrison,et al.  Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.

[106]  S. Wei,et al.  Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase , 1999, Gene Therapy.

[107]  E. Snyder,et al.  Neural Stem Cells as Engraftable Packaging Lines Can Mediate Gene Delivery to Microglia: Evidence from Studying Retroviral env-Related Neurodegeneration , 1999, Journal of Virology.

[108]  J. Barrio,et al.  Assays for noninvasive imaging of reporter gene expression. , 1999, Nuclear medicine and biology.

[109]  J. Roth,et al.  p53 tumor suppressor gene therapy for cancer. , 1999, Oncology.

[110]  R. Bartus.  The blood-brain barrier as a target for pharmacological modulation. , 1999, Current opinion in drug discovery & development.

[111]  B. Gusterson,et al.  Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway , 1999, Gene Therapy.

[112]  A. Rehemtulla,et al.  Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. , 1999, Human gene therapy.

[113]  A. Rehemtulla,et al.  Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. , 1999, Human gene therapy.

[114]  Y. Assaraf,et al.  Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. , 1999, Journal of the National Cancer Institute.

[115]  I. Pastan,et al.  Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. , 1999, Blood.

[116]  X. Breakefield,et al.  Single-Step Conversion of Cells to Retrovirus Vector Producers with Herpes Simplex Virus–Epstein-Barr Virus Hybrid Amplicons , 1999, Journal of Virology.

[117]  D. Klatzmann,et al.  The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase , 1999, Gene Therapy.

[118]  A. Rehemtulla,et al.  Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. , 1999, Cancer research.

[119]  G. Palù,et al.  Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans , 1999, Gene Therapy.

[120]  Bartus Rt.  The blood-brain barrier as a target for pharmacological modulation. , 1999 .

[121]  O. Wildner,et al.  Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. , 1999, Human gene therapy.

[122]  B. Degrève,et al.  Bystander effect of purine nucleoside analogues in HSV-1tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues , 1999, Gene Therapy.

[123]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  X. Breakefield,et al.  Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. , 1999, Journal of the National Cancer Institute.

[125]  D. Curiel,et al.  Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. , 1999, Cancer research.

[126]  D. Klatzmann,et al.  Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. , 1999, Human gene therapy.

[127]  D. Zagzag,et al.  In Vivo and In Vitro Glioma Cell Killing Induced by An Adenovirus Expressing Both Cytosine Deaminase and Thymidine Kinase and Its Association with Interferon-α , 1999 .

[128]  H. Engelhard,et al.  Gene therapy for brain tumors , 2000, Current oncology reports.

[129]  E. A. Chiocca,et al.  Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. , 2000, Journal of neurosurgery.

[130]  X. Breakefield,et al.  Routes of vector application for brain tumor gene therapy Review Article , 2001 .